Application of an innovative isoniazid-loaded biomimetic mineralized bone collagen scaffold in bone defect treatment

growth. Additionally, the scaffolds were implanted into mice to assess degradation and drug sustained release. In a critical bone defect model in SD rats, osteogenesis was detected by Micro-CT, and biocompatibility was evaluated using HE staining of vital organs. The drug loading rate and entrapment efficiency of drug-loaded scaffolds were (6.25 ± 0.48)% and (54 ± 2.34)%, respectively. In co-culture with tuberculosis bacteria, the drug-loaded group showed a negative result in the BACTEC MIGT 960 detection system after continuous observation for more than 8 weeks, contrasting with positive results in the blank and non-drug-loaded groups. At the 8th week, acid-fast staining (AFS), auramine o staining, Micro-CT, and HE staining confirmed the drug-loaded scaffold's antibacterial properties, sustained-release capabilities, biocompatibility, and osteogenesis. Our findings demonstrate that drug-loaded biomimetic mineralized collagen scaffolds exhibit sustained-release properties, biodegradability, antibacterial efficacy, biocompatibility, and osteogenic potential. This novel drug-loaded collagen scaffold holds significant promise for the effective repair of infected bone defects.